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Abstract 
Purpose: It is crucial to obtain a specific diagnosis before treatment of chest pathology is initiated. The purpose of the 
study is to present the utility of percutaneous biopsies, core and fine-needle aspiration, in various thoracic lesions, 
and related complications. 
Material and methods: A total of 593 transthoracic biopsies were performed in the Department of Radiology between 
2013 and 2016. Fine-needle aspiration biopsy (FNAB) and core biopsy (CB) were implemented. The procedures 
were divided into four groups according to the location of the pathology: lung lesions (LL – 540), mediastinal masses 
(MM – 25), chest wall tumours (CWT – 13), and pleural lesions (PL – 15). The lung lesion group was divided into 
two subgroups: lung nodules and lung infiltrations. All groups were analysed in respect of diagnostic accuracy, 
pathological findings, and complication rate. 
Results: Pathological diagnosis was confirmed in 447 cases after all 593 procedures. The sensitivity of malignancy diag-
nosis in the group of lung tumours was 75% for FNAB and 89% for CB. The sensitivity in other groups, where CB was 
a preferable technique, was counted for lung infiltration, mediastinal masses, chest wall tumours, and pleural lesions 
and amounted to 83.3%, 90.9%, 100%, and 85.7%, respectively. In the group of lung tumours malignancy was con-
firmed most commonly (79%), while in the lung infiltration group benign processes dominated (83%). There was no 
statistical difference between the pneumothorax rate after CB and FNAB. Haemoptysis appeared more often after CB. 
Conclusions: FNAB and CB are useful, safe, and sensitive tools in the diagnostic work-up. They can both be used to 
diagnose almost all chest pathologies. 
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Introduction
To obtain a definite diagnosis of chest pathology is not 
an easy task. Groups of pulmonary nodules, lung infiltra-
tions, and other chest pathologies comprise a variety of 
malignant and benign lesions that are difficult to differen-
tiate with use of radiological investigation [1]. 
In numerous studies investigators have evaluated the 
usefulness of transthoracic needle biopsy in the diagnostic 
work-up of lung parenchymal lesions [2-4], but only a few 
studies have elaborated this diagnostic tool for chest wall 
tumours, mediastinal masses, or pleural lesions [5-7]. Both 
fine-needle aspiration and core biopsy have high diagno-
stic accuracy with acceptable complication rates [8, 9]. 
The purpose of the study is to present the diagnostic ac-
curacy, pathological findings, and risk of complications 
connected with the aspiration or core transthoracic needle 
biopsy in various chest pathologies. 
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Material and methods
A total of 593 transthoracic biopsies were performed be-
tween April 2013 and August 2016 in our Radiology De-
partment by the same radiologist. We present a retrospec-
tive analysis of the procedures. 
Figure 1. An example of lung tumour biopsy – typical carcinoid was con-
firmed
Figure 2. An example of lung infiltration biopsy – pulmonary adenocarci-
noma was confirmed 
Figure 3. An example of mediastinal mass biopsy in a male patient – 
primary mediastinal choriocarcinoma was confirmed 
Figure 4. An example of chest wall tumour biopsy – Ewing sarcoma was con-
firmed 
Figure 5. An example of pleural lesion biopsy – pathological evaluation 
confirmed mesothelioma
All biopsies were performed computed tomography 
(CT)- or CT-fluoroscopy-guided and were performed using 
a 128-row CT scanner. 
Fine-needle aspiration biopsy (FNAB) or core biopsy 
(CB) were performed. 
Before the procedure, informed consent was obtained 
in all cases. A 1% solution of lidocaine was used as local 
anaesthesia. 
All performed procedures were divided into four 
groups according to the location of the pathology:
•	 lung lesions (LL) – 540 procedures: all intraparenchy-
mal lesions with probable lung parenchyma origin 
(including lung lesions infiltrating the mediastinum, 
pleura, or chest wall), subdivided into:
 – lung tumours: well-defined nodules with sharp, 
definite margins separating them from healthy 
lung parenchyma,
 – lung infiltration: ill-defined lesions without sharp 
borders, which infiltrate lung parenchyma; 
•	 mediastinum masses (MM) – 25 procedures: both 
mass or lymph nodes located originally in the me-
diastinum (bone or pleural lesions with mediastinal 
involvement were excluded from this group); 
•	 chest wall tumours (CWT) – 13 procedures: masses 
with probable origin within chest wall structures such 
as ribs and muscles (lung tumours with chest wall in-
volvement were excluded from this group); 
•	 pleural lesions (PL) – 15 procedures: pathologies lo-
cated within or between parietal and visceral pleura 
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(lung tumours with pleural infiltration were excluded 
from this group).
Examples of lesions from separate groups are present-
ed in Figures 1-5. For each group specific information 
such as pathological outcomes, sensitivity, and complica-
tion rate is provided.
As regards complications, we noted that all (even the 
smallest) areas of pneumothorax were visualised in the fol-
low-up X-ray the next day after the procedure. Also, we 
analysed the pneumothorax in respect of whether chest 
tube insertion was needed or not. Pneumothorax requiring 
chest drainage was defined as any symptomatic pneumotho-
rax (pain and/or dyspnoea) or pneumothorax surrounding 
the entire lung on plain PA chest X-ray. The decision was 
undertaken by a board-certified thoracic surgeon.
We also noted any alveolar haemorrhages that ap-
peared in follow-up CT scan both with or without fur-
ther haemoptysis. We recorded all cases of blood spitting 
observed after the procedure, including minor spitting 
without the need for drug administration. 
For statistical analysis, raw numbers and percentage 
values were used for descriptive data. Fisher’s exact and 
Wilcoxon tests were used for a comparable analysis of 
separate groups. 
Sensitivity for malignancy detection was calculated. 
The result was considered true positive when a ma-
lignancy revealed after FNAB or CB was confirmed by 
surgical resection or other diagnostic procedure such as 
endobronchial ultrasound-guided biopsy (EBUS), bron-
chofiberoscopy, or thoracoscopy, or when the pathological 
result was sufficient for further treatment. The result was 
considered false negative when biopsy revealed no malig-
nancy, but after surgery or other diagnostic procedure the 
neoplastic character of the tumour was confirmed. 
Negative cases without any further diagnostic work-up or 
CT control were excluded from the sensitivity calculations. 
Results
Biopsy details 
The average size of punctured lung nodules was 27 mm 
and lung infiltration was 41 mm (p < 0.01). In the case of 
lung tumours, both CB and FNAB were performed with 
comparable frequency rate (214 FNAB vs. 292 CB), but in 
the lung infiltration group core biopsy was the preferred 
technique (32 CB vs. 2 FNAB, p < 0.01). 
The mean size of mediastinal tumours was 55 mm and 
chest wall tumours 44 mm. We did not measure the size of 
pleural lesions because most of them were widely spread 
in the entire pleura. Core biopsy was the preferred diag-
nostic technique in all three groups (MM – 84%, CWT 
and PL – 100%). CT fluoroscopy during core biopsy was 
widely used in the MM group (in 85% of procedures) but 
only occasionally in the CWT and PL groups (20-27% of 
procedures). 
For the CB procedures of lung tumours an 18-gauge 
needle was used most commonly, but in other groups of 
lesions higher gauge needles were selected. 
Biopsy details are summarised in Table 1. 
Diagnostic accuracy and pathological outcomes 
Specific pathological diagnosis was confirmed in 447 cases 
after all 593 procedures. Sensitivity of malignancy diag-
nosis in the group of lung tumours was 75% for FNAB 
and 89.1% for CB. Sensitivity in other groups, where CB 
was also the most preferred technique, was counted, re-
spectively, for lung infiltration, mediastinal masses, chest 
wall tumours, and pleural lesions as 83.3%, 90.9%, 100%, 
and 85.7%. 
In the group of lung tumours malignancy was con-
firmed most commonly (79%), but in the lung infiltra-
Table 1. Biopsy details for various groups of pathologies
Lung 
tumours
506 Lung 
infiltration
34 Mediastinal 
masses
25 Chest wall 
tumours
13 Pleural 
lesions
15
Size (mm) 27.2 41.2 55.2 44.3
Biopsy details
FNAB (22-gauge) 214 42.3% 2 5.9% 4 16% 0 0% 0 0%
Use of CT fluoroscopy 4 1.9% 0 0% 2 50%
CB 292 57.7% 32 94.1% 21 84% 13 100% 15 100%
 12-gauge 4 1.3% 1 3.1% 0 0% 3 23% 2 13%
 14-gauge 48 16.5% 9 28.1% 1 4.8% 7 53.8% 4 27%
 16-gauge 87 29.9% 16 50% 15 71.4% 2 15.4% 6 40%
 18-gauge 149 51% 6 18.8% 5 23.8% 1 7.7% 3 20%
 20-gauge 4 1.3% 0 0% 0 0% 0 0% 0 0%
Use of CT fluoroscopy 165 60.8% 0 0% 18 85.7% 3 23% 3 20%
FNAB – fine-needle aspiration biopsy, CT – computed tomography, CB – core biopsy
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Table 2. Diagnostic accuracy calculated for all groups of pathologies
Lung tumours Lung 
infiltration
Mediastinal 
masses
Chest wall 
tumours
Pleural
 lesions
  FNAB CB CB and FNAB CB and FNAB CB CB
Number of procedures 214  292  34  25  13  15 
Diagnosis obtained 131 (61.2%) 241 (82.5%) 30 (88.2%) 21 (84.0%) 13 (100.0%) 11 (73.3%)
Malignant 115 (53.7%) 180 (61.6%) 5 (14.7%) 20 (80.0%) 8 (61.5%) 6 (40.0%)
Benign 16 (7.5%) 60 (20.5%) 25 (3.5%) 1 (4.0%) 5 (38.5%) 5 (33.3%)
No diagnosis 83 (38.8%) 52 (17.8%) 4 (11.8%) 4 (16.0%) 0  (0.0%) 4 (26.7%)
TP 114  180  5  20  8  6 
TN 37  55  21  2  3  5 
Sensitivity 75.0%  89.1%  83.3%  90.9%  100.0%  85.7% 
Not included in calculation 25 (11.7%) 35 (10.8%) 7 (20.6%) 1 (4.0%) 2 (15.4%) 3 (20.0%)
FNAB – fine-needle aspiration biopsy, CB – core biopsy, TP – xxxxxx, TN – xxxxxxx
tion group benign process was revealed more frequently 
(83%). In the MM and CWT group malignant neoplasm 
dominated in pathological analysis, but among pleural 
lesions the rate of malignant and benign processes was 
comparable. 
The most common malignancy in the lung tumour 
group was adenocarcinoma (135 of 295; 46%). Among 
benign nodular lesions, acute or chronic inflammatory 
process was the most common finding (43 of 76; 57%). In-
terstitial diseases and inflammatory processes were most 
commonly confirmed in the lung infiltration group (20 of 
34; 59%). Small cell carcinoma and lymphoma dominated 
among mediastinal pathologies. Metastatic character of 
chest wall tumours was proven in 88% cases. In pleural 
lesions the rate of metastases and benign, fibrotic changes 
was comparable. 
Detailed information about diagnostic accuracy and 
pathological results is presented in Table 2 and Table 3. 
Complications 
In the group of lung tumours pneumothorax was revealed 
on follow-up X-ray in 71 of 214 (33.2%) FNABs and 89 of 
292 (30.5%) CBs, and there was no statistical difference 
between these two techniques (p = 0.2). 
The frequency of chest tube insertion due to pneu-
mothorax was also comparable for each of the techniques 
(p = 0.9) and amounted to 14% for FNAB and 12.3% for 
CB. The frequency of drainage in the lung infiltration 
group after CB was 12.5%, and it was the same as in the 
lung tumour group (p = 0.7). 
The pneumothorax rate in the mediastinal masses 
group was 23.8%, but drainage was necessary in one case 
only. In the other two groups pneumothorax was observed 
occasionally, and it never required further intervention. 
Alveolar haemorrhage was commonly seen after pro-
cedures performed due to lung tumour and lung infil-
tration, and definitely more frequently when core needle 
was used (p < 0.01). Moreover, haemoptysis also was often 
seen after CB, but only occasionally after FNAB (12.3% 
in CB vs. 1.4% in FNAB, p < 0.01). There was no revealed 
haemoptysis after procedures performed due to mediasti-
nal mass, chest wall tumour, or pleural lesion. 
Complications are listed in Table 4. 
Discussion and conclusions
In chest radiology, behind the large variety of radiological 
outcomes stands an even greater number of pathological 
diagnoses. For further treatment it is crucial to differenti-
ate malignant neoplasms from benign processes. In daily 
practice of many institutions CT-guided percutaneous 
needle biopsy is still the gold standard of evaluation of 
chest pathologies [5, 7, 8, 10]. 
In this study we presented our experience in CT-guid-
ed needle biopsies performed due to chest pathologies. In 
our material we found several significant issues:
1. Core biopsy is a more sensitive technique in lung ma-
lignancy detection than fine-needle aspiration biopsy. 
2. Core biopsy is a highly accurate technique for evalua-
tion other chest pathologies such as mediastinal mass-
es, chest wall tumours, or pleural lesions.
3. There is no statistical difference between pneumotho-
rax rate and pneumothorax requiring drainage after 
CB and FNAB. 
4. Haemoptysis was observed more commonly after CB 
than after FNAB.
In a meta-analysis Zhang et al. reported that the sen-
sitivity for FNAB varied between 68% and 95%, and be-
tween 84% and 97% for CB [8]. A comparison of our re-
sults with those from Zhang et al. shows that we obtained 
similar sensitivity for FNAB and CB in evaluation of lung 
tumours. We also observed that CT-guided core biopsy is 
an effective and very safe procedure in the diagnostic field 
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Table 3. Specification of pathological findings in all groups of chest pathologies
Pathological findings Lung tumours Lung 
infiltration
Mediastinal 
masses
Chest wall 
tumours
Pleural 
lesions
Malignant 115  180  5  20  8  6 
Non-specified NSCLC 12 (10.4%) 11 (6.1%) 0 (0.0%) 1 (5.0%) 0 (0.0%) 0 (0.0%)
Adenocarcinoma 59 (51.3%) 76 (42.2%) 3 (60.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Carcinoma planoepitheliale 18 (15.7%) 43 (23.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Neuroendocrine NSCLC 3 (2.6%) 7 (3.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
SCLC 9 (7.8%) 4 (2.2%) 0 (0.0%) 6 (30.0%) 0 (0.0%) 0 (0.0%)
Combined NSCLC + SCLC 5 (4.3%) 3 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Mesothelioma malignum 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (16.7%)
Metastases 9 (7.8%) 30 (16.6%) 2 (40.0%) 3 (15.0%) 7 (87.5%) 5 (83.3%)
Others 0 (0.0%) 6 (3.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Sarcoma 0 (0.0%) 3 (1.9%) 0 (0.0%) 2 (10.0%) 1 (12.5%) 0 (0.0%)
Thymic cancer 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (5.0%) 0 (0.0%) 0 (0.0%)
Choriocarcinoma 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (5.0%) 0 (0.0%) 0 (0.0%)
Lymphoma 0 (0.0%) 3 (0.6%) 0 (0.0%) 6 (30.0%) 0 (0.0%) 0 (0.0%)
Benign 16  60  25  1  5  5 
Sarcoidosis 0 (0.0%) 5 (8.3%) 2 (8.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Tuberculosis 2 (12.5%) 6 (10%) 3 (12.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Inflammatory process 6 (37.5%) 37 (61.7%) 10 (40.0%) 1 (100.0%) 3 (60.0%) 0 (0.0%)
Interstitial disease 0 (0.0%) 3 (5%) 10 (40.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Granulomatosis with polyangiitis 0 (0.0%) 3 (5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Others 8 (50.0%) 6 (10%) 0 (0.0%) 0 (0.0%) 2 (40.0%) 5 (100.0%)
Neurofibroma 0 (0.0%) 2 (3.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Hamartoma 6 (37.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Fibrotic pleural lesions 0 (0.0%) 1 (1.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (100.0%)
Pneumoconiosis 2 (12.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Rheumatoid nodule 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Atypical adenomatous hyperplasia 0 (0.0%) 3 (1.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
NSCLC – non-small cell lung carcer, SCLC – small cell lung cancer
Table 4. Complication after biopsy procedure reported in each group of chest pathologies
Complications Lung tumours Lung infiltration Mediastinal masses Chest wall
tumours
Pleural 
lesions
  FNAB 214 CB 292 FNAB 2 CB 32 FNAB 4 CB 21 CB 13 CB 15
Pneumothorax 71 33.2% 89 30.5% 1 50.0% 8 25.0% 0 0.0% 5 23.8% 0 0.0% 1 8.3%
Pneumothorax without 
chest tube insertion
41 19.2% 53 18.2% 1 50.0% 4 12.5% 0 0.0% 4 19.0% 0 0.0% 1 8.3%
Pneumothorax with
chest tube insertion
30 14.0% 36 12.3% 0 0.0% 4 12.5% 0 0.0% 1 4.8% 0 0.0% 0 0.0%
Alveolar haemorrhage 62 29.0% 113 38.7 % 0 0.0% 10 31.3% 0 0.0% 2 9.5% 0 0.0% 0 0.0%
Haemoptysis 3 1.4% 36 12.3% 0 0.0% 4 12.5% 0 0.0% 0 0.0% 0 0.0% 0 0.0%
Pleural haematoma 3 1.4% 4 1.4% 0 0.0% 0 0.0% 0 0.0% 0 0.0% 0 0.0% 0 0.0%
NAB – fine-needle aspiration biopsy, CB – core biopsy
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References
of other chest pathologies [9]. Other authors also recom-
mended it as the procedure of first choice in the evalua-
tion of mediastinal masses [6], chest wall tumours [7], and 
pleural lesions [5], obviating more invasive procedures 
such as thoracoscopy, mediastinoscopy, or thoracotomy. 
Heering et al. analysed numerous previous studies ac-
cording to complication rate, and noted that the pneumo-
thorax rate and pneumothorax with intervention varied 
greatly (8-50% and 0-19%, respectively) [9]. According to 
their analysis, the pneumothorax rate is strongly connect-
ed with the size of the needle, and its rate is higher after 
CB procedures. Conversely, the pneumothorax and pneu-
mothorax with intervention rate in our study was similar 
in each technique used. However, as in the above-men-
tioned meta-analysis, we found that a thicker needle in-
creased the risk of haemoptysis [9]. 
Conclusions 
Both FNAB and CB are useful, safe, and sensitive tools, 
which can be used in chest pathology diagnostic work-up, 
with acceptably low risk of complications. 
Conflict of interest
The authors report no conflict of interest.
